sprite-preloader
Samstag, 19.04.2014 Börsentäglich über 12.000 News von 475 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: 868270 ISIN: US6285301072 Ticker-Symbol: MYL 
Aktie:
Branche
Pharma
Aktienmarkt
NASDAQ-100
S&P 500
NASDAQ Biotech
1-Jahres-Chart
MYLAN INC Chart 1 Jahr
1-Woche-Intraday-Chart
MYLAN INC 1-Woche-Intraday-Chart
RealtimeGeldBriefZeit
33,902
34,044
17.04.

Aktuelle News zu MYLAN Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:
LeserMedien
MYLAN Aktie jetzt ab 5 Dollar handeln!

--> Artikel lesen
05:07Mylan: Court Denies Injunction Against Generic Version Of Copaxone3
CANONSBURG (dpa-AFX) - Mylan Inc. (MYL) announced that Supreme Court Chief Justice Roberts has denied Teva's application for an injunction seeking to prevent Mylan's launch of a generic version...
--> Artikel lesen
02:47Supreme Court Chief Justice Denies Teva's Request for an Injunction Relating to Generic Copaxone; Clears Legal Hurdle for Mylan to Launch at Market Formation3
PITTSBURGH, April 18, 2014 /PRNewswire/ --Mylan Inc. (Nasdaq: MYL) today announced that Supreme Court Chief Justice Roberts has denied Teva's application for an injunction seeking to prevent Mylan's...
--> Artikel lesen
DoProsonix reaches licensing agreement with Mylan Inc.-

--> Artikel lesen
Do5 things: ExOne rebounds ... Drilling's impact on state's forests ... Allegheny County Airport ... Table games record ... Mylan approval8

--> Artikel lesen
MiUPDATE: Mylan Launches First Generic ORTHO EVRA Patch-

--> Artikel lesen
MiMylan Launches First Generic ORTHO EVRA Patch7
PITTSBURGH, April 16, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched XULANE' (Norelgestromin / Ethinyl Estradiol...
--> Artikel lesen
MiProsonix, Mylan license agreement for generic versions of Flixotide and Flovent1

--> Artikel lesen
MiMylan Inks Two Separate Agreements2

--> Artikel lesen
DiMylan Crosses Pivot Point Support at $45.221

--> Artikel lesen
DiMylan Unveils Generic Lunesta Tablets3
CANONSBURG (dpa-AFX) - Mylan Inc. (MYL) announced that it has launched Eszopiclone Tablets 1 mg, 2 mg and 3 mg, the generic version of Sunovion Pharmaceuticals Inc.'s Lunesta.Mylan received...
--> Artikel lesen
DiMylan Unit, Warner Chilcott Enter Settlement Over Generic Generess Fe Tabs ANDA Filing-

--> Artikel lesen
DiMylan Announces Settlement Agreement for First-to-File Generess Fe1
PITTSBURGH, April 15, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it and its partner Famy Care Ltd. have entered into a settlement and license agreement with Warner Chilcott...
--> Artikel lesen
DiMylan Launches Generic Lunesta Tablets2
PITTSBURGH, April 15, 2014 /PRNewswire/ --Mylan Inc. (Nasdaq: MYL) today announced that it has launched Eszopiclone Tablets 1 mg, 2 mg and 3 mg, the generic version of Sunovion Pharmaceuticals...
--> Artikel lesen
DiTuesday's Top Health Care Stories: Johnson & Johnson, Teva, Mylan, and Dynavax6

--> Artikel lesen
DiProsonix And Mylan Reach Licensing Deal For Inhaled Respiratory Products3
CANONSBURG (dpa-AFX) - Prosonix, a speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announced that it has entered into a global licensing...
--> Artikel lesen
DiLegal Updates, Stock Price Movements, New Awareness Campaigns, and Senior-level Appointments - Analyst Notes on Mylan, WellPoint, Forest, Novatis and Intercept3
NEW YORK, April 15, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Mylan Inc. (NASDAQ: MYL), WellPoint Inc. (NYSE: WLP), Forest Laboratories Inc. (NYSE: FRX),...
--> Artikel lesen
DiProsonix and Mylan Enter Into Global Licensing Agreement for Generic Versions of Inhaled Respiratory Products Flixotide and Flovent4
OXFORD, England and PITTSBURGH, April 15, 2014 /PRNewswire/ --Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, today announced...
--> Artikel lesen
MoFederal judge enforces settlement agreement between Mylan and Endo Pharmaceuticals regarding generic Frova2

--> Artikel lesen
MoMylan to Settle with Endo on Frova-

--> Artikel lesen
11.04.MYLAN INC. - 8-K, Current Report-

--> Artikel lesen
Seite:  Weiter >>
375 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
MYLAN INC-Investoren interessieren sich auch für diese News

Unternehmen / AktienAktienkurs%Top-Nachrichten
STADA ARZNEIMITTEL29,13+0,15 %STADA-Aktie: Leerverkäufer Marshall Wace schießt weiter scharf - Aktiennews
Bad Vilbel - Leerverkäufer Marshall Wace baut Netto-Leerverkaufsposition in Aktien der STADA Arzneimittel AG weiter aus Die Leerverkäufer des Hedgefonds Marshall Wace bauen ihr Short-Engagement in den...
--> Artikel lesen
GILEAD SCIENCES50,94+1,88 %Gilead Sciences-Aktie: Hepatitis C-Medikament Solvadi dominiert den Markt! - Aktienanalyse
Zürich - Gilead Sciences-Aktienanalyse von Analyst Vamil Divan von der Credit Suisse: Aktienanalyst Vamil Divan von der Investmentbank Credit Suisse rechnet laut seiner Aktienanalyse für die Aktien...
--> Artikel lesen
TEVA PHARMACEUTICAL INDUSTRIES36,785+1,00 %Supreme Court Chief Justice Denies Teva's Request for an Injunction Relating to Generic Copaxone; Clears Legal Hurdle for Mylan to Launch at Market Formation
PITTSBURGH, April 18, 2014 /PRNewswire/ --Mylan Inc. (Nasdaq: MYL) today announced that Supreme Court Chief Justice Roberts has denied Teva's application for an injunction seeking to prevent Mylan's...
--> Artikel lesen
NOVO NORDISK31,94+1,98 %Novo Nordisk Launches 'Cities Changing Diabetes' to Fight Urban Diabetes
BAGSVÆRD, Denmark, March 28, 2014 /PRNewswire/ --  Novo Nordisk today announces the launch of 'Cities Changing Diabetes', an ambitious new partnership programme to fight the urban diabetes challenge....
--> Artikel lesen
PFIZER21,90+1,01 %Pfizer-Aktie: Onkologie-Geschäft und Restrukturierungen versprechen Potenzial, Kursziel angepasst! - Aktienanalyse
New York - Pfizer-Aktienanalyse von Analyst Jeffrey Holford von Jefferies & Co: Jeffrey Holford, Aktienanalyst von Jefferies & Co, bleibt in seiner aktuellen Aktienanalyse bei der Kaufempfehlung für...
--> Artikel lesen
Lade...